title: Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6.
abstract: To investigate the role of group II phospholipase A2(PLA2) in cancer, we examined the expression and secretion of group II PLA2 in response to the stimulation of interleukin 6(IL-6) in human gastric cancer cells in vitro. Group II PLA2 determined by a specific radioimmunoassay was constitutively produced in culture supernatant of KATO III (signet ring cell carcinoma) and MKN28 (well differentiated adenocarcinoma). This production in KATO III significantly increased with a treatment of IL-6, whereas that in MKN28 remained at a same level. Moreover, the quantitation by reverse transcription-polymerase chain reaction(RT-PCR) demonstrated the IL-6 inducible overexpression of group II PLA2 mRNA in KATO III. This transcription was mediated by NF-IL6, the same as in hepatocytes. These results suggest two possible mechanisms of group II PLA2 production by cancer cells in vivo, that is, cytokine-induced production and constitutive production.
authors.affiliation: Department of Surgery II, Kumamoto University Medical School, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamashita
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: J
authors.initials: J
authors.lastname: Yamashita
authors.forename: K
authors.initials: K
authors.lastname: Sakamoto
authors.forename: H
authors.initials: H
authors.lastname: Niwa
authors.forename: K
authors.initials: K
authors.lastname: Yamamura
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology; D001483:Base Sequence; D022762:CCAAT-Enhancer-Binding Proteins; D018279:Carcinoma, Signet Ring Cell / Q000201:enzymology / Q000473:pathology; D002460:Cell Line; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000473:pathology; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology*; D007527:Isoenzymes / Q000096:biosynthesis; D007700:Kinetics; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D009687:Nuclear Proteins / Q000096:biosynthesis; D010741:Phospholipases A / Q000096:biosynthesis*; D054467:Phospholipases A2; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D014157:Transcription Factors / Q000096:biosynthesis; D014407:Tumor Cells, Cultured
chemical_list: D022762:CCAAT-Enhancer-Binding Proteins; D017931:DNA Primers; D004268:DNA-Binding Proteins; D015850:Interleukin-6; D007527:Isoenzymes; D009687:Nuclear Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D014157:Transcription Factors; D010741:Phospholipases A; D054467:Phospholipases A2